Clinical Trials Logo

Delivery Uterine clinical trials

View clinical trials related to Delivery Uterine.

Filter by:
  • None
  • Page 1

NCT ID: NCT02655783 Completed - Delivery Uterine Clinical Trials

Use of Normal Saline With or Without Dextrose During Induction of Labor in Nulliparous

DEXTRONS
Start date: January 2013
Phase: N/A
Study type: Interventional

The objective of this study is to compare the effects of use of normal saline (250 cc / h), with or without dextrose supplement, on the evolution of labor in nulliparous.

NCT ID: NCT02570620 Completed - Delivery Uterine Clinical Trials

Contribution of Ultrasonography in the Evaluation of Cervical Induction-delivery Time

ECOLDIA
Start date: September 2010
Phase: N/A
Study type: Interventional

Study of the contribution of ultrasound measurements of the uterine cervix related to the calculation of Bishop score. Evaluation of the period between cervical induction and delivery. Study of ultrasound data to improve the care of these patients requiring induction.

NCT ID: NCT01765881 Completed - Delivery Uterine Clinical Trials

Comparison Between 25 µg Vaginal Misoprostol vs Slow Release Pessary PGE2

CYTOPRO
Start date: September 2012
Phase: Phase 2
Study type: Interventional

For about 10% of pregnancies, it is necessary to induce delivery for medical reasons. Prostaglandins alone can be used to perform cervical ripening in cases of immature cervix. In France, dinoprostone is the own approved medication. It is in the form of gel or sustained release device whose effectiveness and side effects are comparable. The vaginal misoprostol has no marketing authorization in France, but is sometimes used. Some data in the scientific literature have showed that its use with low-dose (25 mcg) vaginally did not lead to more complications, was at least as effective and seems to be cost-effective compared with dinoprostone. Misoprostol with this dose and route of administration is now recommended by the American College of Obstetricians and Gynecologist (ACOG), Grade A (ACOG Practice Bulletin August 2009). This is not the case in France (French HAS 2008 Guidelines on induction of labor). According to HAS, the investigators still lack data on large samples to confirm the benefits of misoprostol 25 mcg vaginally, in terms of efficiency, rate of cesarean section, and lower cost compared to dinoprostone. The primary objective is to demonstrate non-inferiority of vaginal misoprostol 25 mcg vs. dinoprostone in terms of cesarian section occurence with a non-inferiority margin of +5% difference.

NCT ID: NCT01506102 Recruiting - Delivery Uterine Clinical Trials

Thromboelastography During and After Delivery

Start date: November 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to establish reference values for thromboelastography (TEM-A) in healthy pregnant women during labor and 2 hours and 24 hours after delivery.

NCT ID: NCT01505192 Recruiting - Delivery Uterine Clinical Trials

Noninvasive Continuous Measurement of SpHb After Spontaneous Vaginal Delivery

Start date: December 2011
Phase: N/A
Study type: Interventional

Aim of this study is to determine the physiological reference individual values (RI) of maternal continuous SpHb immediately after delivery in the post-partum period (continuous monitoring up to 2 hours after delivery) in order to establish the physiological Hb variations in response to the physiological blood loss due to delivery. During labor all parturients will be tested for standard Laboratory Hb and monitored for at least 30 minutes with SpHb monitoring equipment (Radical-7™ Pulse CO-Oximeter and Rainbow DiSposable™ Adult Adhesive Sensor), and these values will be considered to be the baseline values. Immediately after spontaneous vaginal delivery, venous blood sample will be taken for Hb determination and Radical 7 equipment for SpHb will be connected to the patient's finger and will be recorded for at least two hours after delivery. At the end of this period of observation a venous blood sample will be taken for Hb determination. Additional measurements of both SpHb and Lab Hb will be performed 24 hours after delivery.